Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients-A Comprehensive Review

Benoît Henry1, Alain Lefevre Utile2, Stephane Jaureguiberry1,3

  • 1Service des Maladies Infectieuses et Tropicales, APHP, Hôpital Universitaire de Bicêtre, 94275 Le Kremlin-Bicêtre, France.

Insights

Intra-abdominal and gastrointestinal mucormycosis are rare but deadly fungal infections. Early suspicion and diagnosis, particularly in ICU patients, are crucial for effective treatment and improved outcomes.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Intra-abdominal and gastrointestinal mucormycosis are infrequent but highly lethal infections.
  • Diagnosis is challenging due to non-specific clinical presentations.

Purpose of the Study:

  • To review epidemiological, clinical, and therapeutic data of intra-abdominal and gastrointestinal mucormycosis.
  • To identify key factors influencing patient outcomes.

Main Methods:

  • Systematic review of English-language case reports published up to October 2024.
  • Analysis of 290 cases in non-hematological, non-neonatal patients.
  • Data collection on demographics, predisposing conditions, clinical presentation, diagnosis, and treatment.

Main Results:

  • Most cases originated from India and the USA.
  • Common predisposing factors include diabetes, solid organ transplant, ICU stay, and corticosteroid use.
  • The stomach was the most common site; abdominal pain, vomiting, and GI bleeding were frequent symptoms.
  • Histology was the primary diagnostic method, followed by mycology and molecular techniques.
  • Mortality was 52.9%, reduced with intravenous amphotericin B and surgery.

Conclusions:

  • Early suspicion and prompt diagnosis are vital for favorable outcomes in gastrointestinal and intra-abdominal mucormycosis.
  • Consider mucormycosis in ICU patients with risk factors presenting with abdominal symptoms.
  • Integrated mycological diagnosis aids rapid identification and treatment initiation.